Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant tumors

Chen,Xi; Dong,Ke; Long,Min; Lin,Fang; Wang,Xi; Wei,Junxia; Ren,Jihong; Zhang,Huizhong

doi:10.3892/ol.2012.734

Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant tumors

Authors:
- Xi Chen
- Ke Dong
- Min Long
- Fang Lin
- Xi Wang
- Junxia Wei
- Jihong Ren
- Huizhong Zhang
View Affiliations

Affiliations: Department of Medicine Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China, Department of Medicine Laboratory and Research Center, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: May 25, 2012 https://doi.org/10.3892/ol.2012.734
Pages: 319-323

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant tumors are the leading cause of mortality worldwide. The search for new biomarkers for the early diagnosis of the onset of cancer to reduce high mortality is crucial. The potential of minimal invasive testing using serum from patients renders auto-antibodies promising biomarkers for cancer diagnosis. In this study, a 181 amino acid peptide of extracellular astrocyte elevated gene-1 (AEG-1) was expressed and purified, and the peptide was used in an ELISA assay to detect anti-AEG-1 auto-antibodies (AEG-1-Abs) in 483 serum samples from different cancer patients and 230 serum samples from normal blood donors. The results showed that AEG-1-Abs at titers ≥1:50 were detected in 238 of 483 (49%) cancer patients, and the positive antibody responses in different cancer patients were as follows: 44 of 98 (45%) in breast cancer patients, 48 of 96 (50%) in hepatic carcinoma patients, 43 of 88 (49%) in rectal cancer patients, 51 of 113 (45%) in lung cancer patients, and 52 of 88 (59%) in gastric cancer patients. These results were compared with 0 of 230 (0%) in normal individuals. Moreover, AEG-1-Abs at titers ≥1:50 were also detected in 24 of 94 (26%) cancer patients in TNM stages I and II, and the positive rates of AEG-1-Abs decreased with age. These results suggest that the AEG-1-Ab response acts as a diagnostic biomarker for cancer patients with AEG-1-positive expression, and may also prove to be a possible inducer, with substantial immunity against AEG-1 by immunization boosting with AEG-1 vaccines.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality. Worldwide: IARC CancerBase No. 10. Lyon, France. http://globocan.iarc.fr.
2	Caron M, Choquet-Kastylevsky G and Joubert-Caron R: Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics. 6:1115–1122. 2007. View Article : Google Scholar : PubMed/NCBI
3	Desmetz C, Cortijo C, Mange A and Solassol J: Humoral response to cancer as a tool for biomarker discovery. Proteomics. 72:982–988. 2009. View Article : Google Scholar : PubMed/NCBI
4	Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y and Chan EKL: Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. Hepatology. 46:107–114. 2007. View Article : Google Scholar
5	Tan EM and Zhang JY: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 222:328–340. 2008. View Article : Google Scholar : PubMed/NCBI
6	Lu HL, Goodell V and Disis ML: Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res. 7:1388–1394. 2008. View Article : Google Scholar : PubMed/NCBI
7	Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 15:3363–3367. 1997.PubMed/NCBI
8	Shimbo T, Tanemura T, Yamazaki T, Tamai K, Katayama I and Kaneda Y: Serum anti-BPAG1 auto-antibody is a novel marker for human melanoma. PLoS One. 5:e10566–e10573. 2010. View Article : Google Scholar : PubMed/NCBI
9	Defresne F, Bouzin C, Guilbaud C, et al: Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarker. Neoplasia. 12:562–570. 2010.PubMed/NCBI
10	Su ZZ, Kang DC, Chen Y, et al: Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization. Oncogene. 21:3592–3602. 2002. View Article : Google Scholar
11	Kang DC, Su ZZ, Sarkar D, et al: Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 353:8–15. 2005. View Article : Google Scholar : PubMed/NCBI
12	Yoo BK, Emdad L, Su ZZ, et al: Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 119:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
13	Hu GH, Chong RA, Yang QF, et al: MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 15:9–20. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kikuno N, Shiina H, Urakami S, et al: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene. 26:7647–7655. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yu CP, Chen K, Zheng HQ, et al: Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis. 30:894–901. 2009. View Article : Google Scholar : PubMed/NCBI
16	Lee SG, Jeon HY, Su ZZ, et al: Astrocyte elevated gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene. 28:2476–2484. 2009. View Article : Google Scholar : PubMed/NCBI
17	Emdad L, Sarkar D, Su ZZ, et al: Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Therapeut. 114:155–170. 2007. View Article : Google Scholar : PubMed/NCBI
18	Lawrence N and Chin KL: The metastasis problem gets stickier. Cancer Cell. 15:1–2. 2009. View Article : Google Scholar
19	Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ and Fisher PB: Molecular basis of nuclear factor-κB activation by astrocyte elevated gene-1. Cancer Res. 68:1478–1484. 2008.
20	Emdad L, Sarkar D, Su ZZ, et al: Activation of the nuclear factor κB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res. 66:1509–1516. 2006.
21	Emdad L, Lee SG, Su ZZ, et al: Astrocyte elevated gene-1 (AEG-1) functions as an oncogene and regulates angiogenesis. Proc Natl Acad Sci USA. 15:21300–21305. 2009. View Article : Google Scholar : PubMed/NCBI
22	Khuda II, Koide N, Noman ASM, et al: Astrocyte elevated gene-1 (AEG-1) is induced by lipopolysaccharide as toll-like receptor 4 (TLR4) ligand and regulates TLR4 signaling. Immunol. 128:e700–e706. 2009. View Article : Google Scholar : PubMed/NCBI
23	Brown DM and Ruoslahti E: Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell. 5:365–374. 2004. View Article : Google Scholar : PubMed/NCBI
24	Dong J, Zeng BH, Xu LH, et al: Anti-CDC25B auto antibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma. J Transl Med. 8:81–88. 2010. View Article : Google Scholar : PubMed/NCBI
25	Soussi T: p53 antibodies in the sera of patients with various types of cancer. Cancer Res. 60:1777–1788. 2000.PubMed/NCBI
26	Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 30:403–408. 1982. View Article : Google Scholar : PubMed/NCBI